Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAILOR phage cocktail is not a single drug product but a personalized medicine platform developed by the TAILOR (Tailored Antibacterials and Innovative Laboratories for Phage Research) initiative at Baylor College of Medicine. [7, 12] This platform creates customized bacteriophage cocktails for patients with antibiotic-resistant bacterial infections. [7] The process involves isolating the specific bacterial strain from a patient, screening TAILOR's extensive phage library to identify viruses (bacteriophages) that effectively kill the bacteria, and then formulating these selected phages into a personalized therapeutic cocktail. [6, 11] These cocktails are developed for individual patients under compassionate use or Investigational New Drug (IND) applications submitted to the FDA. [6, 17] The mechanism of action is the targeted lysis (killing) of pathogenic bacteria by the bacteriophages in the cocktail. [9] The technology is being commercialized by a spin-off company, PHIOGEN. [8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TAILOR phage cocktail.